AC
BCLI

Armistice Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Armistice Capital’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-690,666
Closed -$870K – 210
2025
Q1 		$870K Buy
+690,666
New +$1.22M 0.01% 170
2024
Q4 		– Sell
-459,844
Closed -$1.59M – 239
2024
Q3 		$1.59M Sell
459,844
-68,000
-13% -$321K 0.03% 162
2024
Q2 		$2.68M Buy
+527,844
New +$3.96M 0.03% 139

Other funds holding BCLI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gunderson Capital Management Mt. Pleasant, South Carolina $370M AUM 211.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
AIP
Almanack Investment Partners Wayne, Pennsylvania $785M AUM 34.37% 1-Year Est. Return

Armistice Capital's BCLI Position: Q2 2025 in Review

Armistice Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2025, closing a stake of 690,666 shares — an estimated $870K sold.

Armistice Capital first reported a position in BCLI in Q2 2024 and held it in 3 quarters. The position peaked at $2.68M in Q2 2024. 34 funds tracked by Wall St. Rank hold BCLI as of Q2 2025.

  • Armistice Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2025 after selling out during the quarter.
  • Armistice Capital sold 690,666 BRAINSTORM CELL THERAPUTC shares in Q2 2025, an estimated $870K.
  • Armistice Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2024 and held it in 3 quarters.
  • Armistice Capital's BRAINSTORM CELL THERAPUTC position peaked at $2.68M in Q2 2024.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.